A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs INCB 59872 (Primary)
- Indications Acute myeloid leukaemia; Cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 12 Oct 2016 Status changed from not yet recruiting to recruiting.
- 17 Mar 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
- 14 Jan 2016 New trial record